000263619 001__ 263619
000263619 005__ 20240403131750.0
000263619 0247_ $$2pmc$$apmc:PMC10527970
000263619 0247_ $$2doi$$a10.1111/nan.12921
000263619 0247_ $$2ISSN$$a0305-1846
000263619 0247_ $$2ISSN$$a1365-2990
000263619 0247_ $$2altmetric$$aaltmetric:150781450
000263619 0247_ $$2pmid$$apmid:37386798
000263619 037__ $$aDZNE-2023-00841
000263619 041__ $$aEnglish
000263619 082__ $$a610
000263619 1001_ $$aHirsch-Reinshagen, Veronica$$b0
000263619 245__ $$aPsychotic symptoms in frontotemporal dementia with TDP‐43 tend to be associated with type B pathology
000263619 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2023
000263619 3367_ $$2DRIVER$$aarticle
000263619 3367_ $$2DataCite$$aOutput Types/Journal article
000263619 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1694702715_30858
000263619 3367_ $$2BibTeX$$aARTICLE
000263619 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000263619 3367_ $$00$$2EndNote$$aJournal Article
000263619 520__ $$a Psychotic symptoms are increasingly recognized as a distinguishing clinical feature in patients with dementia due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Within this group, carriers of the C9orf72 repeat expansion are particularly prone to develop delusions and hallucinations.The present retrospective study sought to provide novel details about the relationship between FTLD-TDP pathology and the presence of psychotic symptoms during life.We found that FTLD-TDP subtype B was more frequent in patients with psychotic symptoms than in those without. This relationship was present even when corrected for the presence of C9orf72 mutation, suggesting that pathophysiological processes leading to the development of subtype B pathology may increase the risk of psychotic symptoms. Within the group of FTLD-TDP cases with subtype B pathology, psychotic symptoms tended to be associated with a greater burden of TDP-43 pathology in the white matter and a lower burden in lower motor neurons. When present, pathological involvement of motor neurons was more likely to be asymptomatic in patients with psychosis.This work suggests that psychotic symptoms in patients with FTLD-TDP tend to be associated with subtype B pathology. This relationship is not completely explained by the effects of the C9orf72 mutation and raises the possibility of a direct link between psychotic symptoms and this particular pattern of TDP-43 pathology.
000263619 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000263619 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000263619 650_7 $$2Other$$aALS
000263619 650_7 $$2Other$$aFTLD-TDP
000263619 650_7 $$2Other$$afrontotemporal dementia
000263619 650_7 $$2Other$$ahistology
000263619 650_7 $$2Other$$apsychosis
000263619 650_7 $$2NLM Chemicals$$aC9orf72 Protein
000263619 650_7 $$2NLM Chemicals$$aDNA-Binding Proteins
000263619 650_7 $$2NLM Chemicals$$aTARDBP protein, human
000263619 650_2 $$2MeSH$$aHumans
000263619 650_2 $$2MeSH$$aC9orf72 Protein: genetics
000263619 650_2 $$2MeSH$$aDNA-Binding Proteins: genetics
000263619 650_2 $$2MeSH$$aFrontotemporal Dementia: genetics
000263619 650_2 $$2MeSH$$aFrontotemporal Dementia: pathology
000263619 650_2 $$2MeSH$$aFrontotemporal Lobar Degeneration: pathology
000263619 650_2 $$2MeSH$$aPsychotic Disorders: complications
000263619 650_2 $$2MeSH$$aRetrospective Studies
000263619 7001_ $$aHercher, Christa$$b1
000263619 7001_ $$aVila-Rodriguez, Fidel$$b2
000263619 7001_ $$0P:(DE-2719)2810592$$aNeumann, Manuela$$b3$$udzne
000263619 7001_ $$aRademakers, Rosa$$b4
000263619 7001_ $$aHoner, William G.$$b5
000263619 7001_ $$aHsiung, Ging-Yuek R.$$b6
000263619 7001_ $$aMackenzie, Ian R.$$b7
000263619 773__ $$0PERI:(DE-600)2008293-9$$a10.1111/nan.12921$$gVol. 49, no. 4, p. e12921$$n4$$pe12921$$tNeuropathology & applied neurobiology$$v49$$x0305-1846$$y2023
000263619 8564_ $$uhttps://pub.dzne.de/record/263619/files/DZNE-2023-00841.pdf$$yOpenAccess
000263619 8564_ $$uhttps://pub.dzne.de/record/263619/files/DZNE-2023-00841.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000263619 909CO $$ooai:pub.dzne.de:263619$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000263619 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810592$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000263619 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000263619 9141_ $$y2023
000263619 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000263619 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000263619 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROPATH APPL NEURO : 2022$$d2024-02-05
000263619 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-02-05
000263619 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-02-05
000263619 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-02-05
000263619 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-02-05
000263619 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-02-05
000263619 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-02-05
000263619 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-02-05
000263619 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-02-05
000263619 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROPATH APPL NEURO : 2022$$d2024-02-05
000263619 9201_ $$0I:(DE-2719)1210003$$kAG Neumann$$lMolecular Neuropathology of Neurodegenerative Diseases$$x0
000263619 980__ $$ajournal
000263619 980__ $$aVDB
000263619 980__ $$aUNRESTRICTED
000263619 980__ $$aI:(DE-2719)1210003
000263619 9801_ $$aFullTexts